Damora Therapeutics (DMRA) Income towards Parent Company (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Income towards Parent Company data on file, last reported at -$27.8 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 996.84% year-over-year to -$27.8 million; the trailing twelve-month figure through Mar 2026 stood at -$231.2 million (down 3133.97% YoY), and the FY2025 full-year result was -$206.0 million, down 1940.61% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$27.8 million, up from -$196.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $4.6 million in Q4 2024 and bottomed at -$196.9 million in Q4 2025.
• The 5-year median for Income towards Parent Company is -$8.1 million (2023), against an average of -$20.2 million.
• The widest annual swing landed in 2024, when Income towards Parent Company soared 171.1%; it then plunged 4376.19% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$13.5 million in 2022, then soared by 52.13% to -$6.5 million in 2023, then jumped by 171.1% to $4.6 million in 2024, then slumped by 4376.19% to -$196.9 million in 2025, then jumped by 85.89% to -$27.8 million in 2026.
• The last three Income towards Parent Company figures came in at -$27.8 million (Q1 2026), -$196.9 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.

Peer Comparison